middle.news
Ceryvyn Therapeutics reports A$330 million profit after DFA settlement and pivots to rare lung disease therapy development
6:27pm on Monday 31st of August, 2026 AEST
•
Biotechnology
Read Story
Ceryvyn Therapeutics reports A$330 million profit after DFA settlement and pivots to rare lung disease therapy development
6:27pm on Monday 31st of August, 2026 AEST
Key Points
FY26 profit of A$330 million after prior year loss of A$251 million
Gain of A$357 million from derecognition of Development Funding Agreement liability
Pivot to CYV-101 inhaled therapy targeting rare lung disease LAM
A$30 million cash on hand, no debt, stage-gated clinical development planned
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Ceryvyn Therapeutics (ASX:CYV)
OPEN ARTICLE